Long-Term Outcomes of Guselkumab and Risankizumab for the Management of Moderate-to-Severe Psoriasis in the Elderly: Results from a Real-World Retrospective Study.
Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Ioannis-Alexios Koumprentziotis1st Department of Dermatology and Venereology, "Andreas Sygros" Hospital for Skin Diseases, National & Kapodistrian University of Athens Medical School, 16121 Athens, Greece.ORCID 0000-0002-1156-7139
Irene Stefanaki1st Department of Dermatology and Venereology, "Andreas Sygros" Hospital for Skin Diseases, National & Kapodistrian University of Athens Medical School, 16121 Athens, Greece.ORCID 0000-0002-2964-370X
Eleni Routsi1st Department of Dermatology and Venereology, "Andreas Sygros" Hospital for Skin Diseases, National & Kapodistrian University of Athens Medical School, 16121 Athens, Greece.ORCID 0000-0002-0480-8520
Charitomeni Vavouli1st Department of Dermatology and Venereology, "Andreas Sygros" Hospital for Skin Diseases, National & Kapodistrian University of Athens Medical School, 16121 Athens, Greece.
Pantelis Panagakis1st Department of Dermatology and Venereology, "Andreas Sygros" Hospital for Skin Diseases, National & Kapodistrian University of Athens Medical School, 16121 Athens, Greece.
Marina Papoutsaki1st Department of Dermatology and Venereology, "Andreas Sygros" Hospital for Skin Diseases, National & Kapodistrian University of Athens Medical School, 16121 Athens, Greece.
Maria Politou1st Department of Dermatology and Venereology, "Andreas Sygros" Hospital for Skin Diseases, National & Kapodistrian University of Athens Medical School, 16121 Athens, Greece.
Aristeidis Vaiopoulos1st Department of Dermatology and Venereology, "Andreas Sygros" Hospital for Skin Diseases, National & Kapodistrian University of Athens Medical School, 16121 Athens, Greece.ORCID 0000-0002-8838-5309
Evdoxia Panou1st Department of Dermatology and Venereology, "Andreas Sygros" Hospital for Skin Diseases, National & Kapodistrian University of Athens Medical School, 16121 Athens, Greece.ORCID 0000-0002-8869-3889
Vasiliki Chasapi1st Department of Dermatology and Venereology, "Andreas Sygros" Hospital for Skin Diseases, National & Kapodistrian University of Athens Medical School, 16121 Athens, Greece.
Alexander Stratigos1st Department of Dermatology and Venereology, "Andreas Sygros" Hospital for Skin Diseases, National & Kapodistrian University of Athens Medical School, 16121 Athens, Greece.
Electra Nicolaidou1st Department of Dermatology and Venereology, "Andreas Sygros" Hospital for Skin Diseases, National & Kapodistrian University of Athens Medical School, 16121 Athens, Greece.ORCID 0000-0002-8221-0217
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Long-Term Outcomes of Guselkumab and Risankizumab for the Management of Moderate-to-Severe Psoriasis in the Elderly: Results from a Real-World Retrospective Study. · full record | Socratic